TRB-071
/ TRex Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 13, 2024
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
(Businesswire)
- "Proceeds from the financing will be used to advance TRexBio’s lead candidate, TRB-061, a purpose-engineered TNFR2 agonist, through early clinical proof of concept in patients with immune mediated diseases including atopic dermatitis and ulcerative colitis....TRexBio expects to initiate a Phase 1 clinical trial with TRB-061 in the first half of 2025. The funding will also support the expansion of TRexBio’s pipeline, including early development of therapeutic candidate TRB-071."
Financing • New P1 trial • Pipeline update • Atopic Dermatitis • Ulcerative Colitis
1 to 1
Of
1
Go to page
1